Sympathetic nervous activation in obesity and the metabolic syndrome-Causes, consequences and therapeutic implications

被引:245
|
作者
Lambert, Gavin W. [1 ]
Straznicky, Nora E. [1 ,2 ,3 ]
Lambert, Elisabeth A. [1 ,2 ,3 ]
Dixon, John B. [1 ,4 ]
Schlaich, Markus P. [1 ,2 ,3 ]
机构
[1] Baker IDI Heart & Diabet Inst, Human Neurotransmitters Lab, Melbourne, Vic 8008, Australia
[2] Baker IDI Heart & Diabet Inst, Neurovasc Hypertens Lab, Melbourne, Vic 8008, Australia
[3] Baker IDI Heart & Diabet Inst, Kidney Dis Lab, Melbourne, Vic 8008, Australia
[4] Monash Univ, Obes Res Ctr, Dept Gen Practice, Clayton, Vic 3800, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Overweight; Metabolic syndrome; Sympathetic nervous system; Microneurography; Target organ damage; BODY-MASS-INDEX; CONVERTING ENZYME-INHIBITION; POSITIVE AIRWAY PRESSURE; LEFT-VENTRICULAR MASS; CARDIOVASCULAR RISK-FACTORS; PREDICT INSULIN-RESISTANCE; MAJOR DEPRESSIVE DISORDER; SLEEP-APNEA SYNDROME; 3RD NATIONAL-HEALTH; END-POINT REDUCTION;
D O I
10.1016/j.pharmthera.2010.02.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The world wide prevalence of obesity and the metabolic syndrome is escalating. Contrary to earlier experimental evidence, human obesity is characterised by sympathetic nervous activation, with the outflows to both the kidney and skeletal muscle being activated. While the mechanisms responsible for initiating the sympathetic activation remain to be unequivocally elucidated, hyperinsulinemia, obstructive sleep apnoea, increased circulating adipokines, stress and p adrenergic receptor polymorphisms are implicated. The pattern of sympathetic activation may be the pathophysiological mechanism underpinning much obesity-related illnesses with the consequences including, amongst others, the development of hypertension, insulin resistance, diastolic dysfunction and renal impairment. While diet and exercise are the first line therapy for the treatment of obesity and the metabolic syndrome, pharmacological interventions targeting the sympathetic nervous system, either directly or indirectly are also likely to be of benefit. Importantly, the benefit may not necessarily be weight related but may be associated with a reduction in end organ damage. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:159 / 172
页数:14
相关论文
共 50 条
  • [31] Obesity-Related Metabolic Syndrome: Mechanisms of Sympathetic Overactivity
    Canale, Maria Paola
    di Villahermosa, Simone Manca
    Martino, Giuliana
    Rovella, Valentina
    Noce, Annalisa
    De Lorenzo, Antonino
    Di Daniele, Nicola
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2013, 2013
  • [32] Small artery remodelling in hypertension: causes, consequences and therapeutic implications
    Mulvany, Michael J.
    MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING, 2008, 46 (05) : 461 - 467
  • [33] Respiratory manifestations of panic disorder: causes, consequences and therapeutic implications
    Sardinha, Aline
    da Rocha Freire, Rafael Christophe
    Zin, Walter Araujo
    Nardi, Antonio Egidio
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2009, 35 (07) : 698 - 708
  • [34] Small artery remodelling in hypertension: causes, consequences and therapeutic implications
    Michael J. Mulvany
    Medical & Biological Engineering & Computing, 2008, 46 : 461 - 467
  • [35] Obesity and the metabolic syndrome: Implications for dietetics practitioners
    Bray, GA
    Champagne, CM
    JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2004, 104 (01) : 86 - 89
  • [36] Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences
    Hong, So-hyeon
    Choi, Kyung Mook
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (02)
  • [37] Metabolic syndrome in patients with systemic lupus erythematosus: Causes and consequences
    Gabriel Erdozain, Jose
    Ruiz Irastorza, Guillermo
    MEDICINA CLINICA, 2015, 144 (07): : 309 - 311
  • [38] PAI-1 and the metabolic syndrome - Links, causes, and consequences
    Alessi, Marie-Christine
    Juhan-Vague, Irene
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (10) : 2200 - 2207
  • [39] The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?
    Lansdown, Andrew
    Rees, D. Aled
    CLINICAL ENDOCRINOLOGY, 2012, 77 (06) : 791 - 801
  • [40] The metabolic syndrome in hypertension:: Diagnostic and therapeutic implications
    Redon, Josep
    Cifkova, Renata
    CURRENT HYPERTENSION REPORTS, 2007, 9 (04) : 305 - 313